Specify a stock or a cryptocurrency in the search bar to get a summary
Lipella Pharmaceuticals Inc. Common Stock
LIPOLipella Pharmaceuticals Inc., a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD). Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania. Address: 7800 Susquehanna St., Pittsburgh, PA, United States, 15208
Analytics
WallStreet Target Price
2 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures LIPO
Dividend Analytics LIPO
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History LIPO
Stock Valuation LIPO
Financials LIPO
Results | 2019 | Dynamics |